Amylyx Pharmaceuticals (AMLX) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.39

Estimate

-$0.36

Surprise

-9.0%

Score today

4.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Amylyx Pharmaceuticals (AMLX) reported a wider loss than forecast — diluted EPS of -$0.39 against the -$0.36 estimate (a 9.0% shortfall).

TrendMatrix currently rates AMLX Sell at 4.7/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -9.0% surprise compares with a +2.1% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$34.07

Price target

$36.86

Stop

$31.69

Upside to target

+8.2%

Reward-to-risk

0.6:1

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$3.78B

P/E (fwd)

-29.4

52-week range

$9.75–$41.14

Off 52-week high

17.2%

RSI (14)

75

Volume vs avg

0.11×

Score today

4.7/10